Print Friendly and PDF

5 Stocks to Buy Now


One fund manager sees earnings growth potential for CarMax stock

Stocks started out strong this year, but grew more volatile as talk of a trade war heated up. On top of that, substantial risks are building in this aged bull market and in an economic expansion that in July becomes the longest one ever.

Even so, Kiplinger's Personal Finance, www.Kiplinger.com, found five stocks worth buying now.

1. CarMax (KMX) – In December, CarMax the country's largest used-car retailer, debuted a new business model in Atlanta, where customers can complete the entire car-buying process online or shop in the store. The Atlanta branch has already seen a bump in sales, and the firm plans to roll out the new car-buying process to the majority of its customers by February 2020. The rollout is not yet reflected in the firm's shares, which trade at just 15 times projected earnings over the next four quarters, says Ira Rothberg, manager of the Hennessy Focus Fund. He sees annualized earnings growth percentages in the mid-teens over the next decade on the strength of new stores, increasing sales and aggressive stock buybacks.

2. Cisco Systems (CSCO) – Cisco is the dominant player in internet switches and routers, but about 40 percent of overall sales comes from steady revenue streams in its software and services businesses. Cisco's $34.6 billion in cash and short-term investments gives it plenty of latitude to raise dividends or make acquisitions. The stock yields 2.5 percent. In May, the company reported that fiscal third-quarter earnings were 13 percent above the same period in 2018. And company executives said during a quarterly earnings call that Cisco has slashed its manufacturing in China, reducing potential damage from a trade war between the U.S. and China.

3. Danaher (DHR) – The company is a health care equipment maker on a hot streak. Shares are up nearly 30 percent so far in 2019 and trade at 26 times projected year-ahead earnings. And yet, says Mike Bailey, director of research at FBB Capital Partners, the market doesn't fully appreciate the growth potential stemming from Danaher's recent mega-acquisition of General Electric's biopharmaceutical business. The unit is a leading provider of instruments, equipment and software supporting the discovery, development and manufacture of complex, biologic drugs. "They need tools to develop these drugs, and Danaher is a major player," Bailey says.

4. Walmart (WMT) – Not many retailers can give Amazon.com a run for its money, but Walmart is giving it a go. Analysts at CFRA bumped up their rating on the stock from "buy" to "strong buy" after the retailer reported boffo first-quarter earnings, including a 37 percent jump in U.S. e-commerce sales. The retailer also announced plans to introduce free next-day shipping on orders over $35. "We think the offer will help it take e-commerce market share from Amazon," say CFRA analysts. They see the stock trading at $115 within the next 12 months.

5. Zoetis (ZTS) – Ahead of the 2020 election, talk of potential Medicare and Medicaid changes, among other things, has spooked many health care investors. But Zoetis, the world's biggest animal health company, is immune to election-year rhetoric. Every major division of its business, which makes vaccines, medicine and health products for a diverse lineup of livestock and pets, expanded in 2018. Managers at Eaton Vance Worldwide Health Sciences fund like the firm's predictable revenue and its growing overseas footprint.

The Bull & Bear Financial Report

Copyright 2018 - 20 || All Rights Reserved
Reproduction in whole or part is strictly prohibited
without prior written permission.


NOTE: The Bull & Bear Financial Report does not itself endorse or guarantee
the accuracy or reliability of information, statements or opinions
expressed by any individuals or organizations posted on this site


The Bull & Bear Financial Report is published by
BULL & BEAR MEDIA GROUP, INC.
Editor@TheBullandBear.com

Website Designed & Maintained by Gemini Communications

PLEASE READ DISCLAIMER